Top-News
Biotechnologie Großbritannien

Adaptimmune Therapeutics Plc. ADR News

Aktie
WKN:  A14SUX ISIN:  US00653A1079 US-Symbol:  ADAP
0,97 €
+0,01 €
+1,04%
21.05.24 19:08:14
Handeln Depot/Watchlist
Aktienanzahl *
227,12 Mio.
Marktkapitalisierung *
230,07 Mio. €
Streubesitz
-
Faktor
6
Originalaktie
GB00BVYV1687
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 03.01.2024

Unternehmensmeldungen

08.01.18 - GlobeNewswire
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company Successful Manufacturing of SPEAR T-...
06.11.17 - GlobeNewswire
Adaptimmune marks Official Opening of U.K. Headquarters
Adaptimmune marks Official Opening of U.K. Headquarters Flagship Facility is new Base for U.K. Research and Development Operations PHILADELPHIA and OXFORD, U.K., Nov. ...
07.09.17 - GlobeNewswire
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune ...
27.03.17 - GlobeNewswire
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters' Option to Purchase Additional American Depositary Shares PHILADELPHIA and ...
22.03.17 - GlobeNewswire
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares PHILADELPHIA and OXFORD, United Kingdom, 2017-03-22  (GLOBE NEWSWIRE) -- Adap...
15.03.17 - GlobeNewswire
Adaptimmune Broadens Executive Team
Adaptimmune Broadens Executive Team PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), ...
13.03.17 - GlobeNewswire
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results - Opened two new INDs for wholly-​owned SPEAR® T-cell therapies; Company now has four open INDs ...
05.12.16 - GlobeNewswire
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune ...
10.11.16 - GlobeNewswire
Adaptimmune Reports Third Quarter 2016 Financial Results
Adaptimmune Reports Third Quarter 2016 Financial Results - U.S. Food and Drug Administration (FDA) lifted partial clinical hold of myxoid/round cell liposarcoma (MRCLS) study of ...
27.10.16 - GlobeNewswire
Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma ...
26.09.16 - GlobeNewswire
MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers
MD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers PHILADELPHIA and HOUSTON, ...
08.08.16 - GlobeNewswire
Adaptimmune Reports Second Quarter 2016 Financial Results
Adaptimmune Reports Second Quarter 2016 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA and OXFORD, United Kingdom, ...
03.08.16 - GlobeNewswire
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma PHILADELPHIA and OXFORD, United ...
21.06.16 - GlobeNewswire
Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System
Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific's Dynabeads(TM) CD3/CD28 Cell Therapy System PHILADELPHIA and ...
20.06.16 - GlobeNewswire
Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR(TM) T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue ...
12.05.16 - GlobeNewswire
Adaptimmune Reports First Quarter 2016 Financial Results
Adaptimmune Reports First Quarter 2016 Financial Results PHILADELPHIA and OXFORD, United Kingdom, May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...
07.04.16 - GlobeNewswire
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer PHILADELPHIA and OXFORD, United Kingdom, ...
17.03.16 - GlobeNewswire
Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015 PHILADELPHIA and OXFORD, United Kingdom, March 17, 2016 (GLOBE NEWSWIRE) ...
09.02.16 - GlobeNewswire
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma ...
02.02.16 - GlobeNewswire
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration Agreement accelerates development of Adaptimmune's lead T-cell therapy targeting NY-ESO-1 toward ...

Newssuche

Videos

newspaper
17.05.24 -6,64%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »